Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

D.Western Therapeutics Institute Inc (4576)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
104.0 -1.0    -0.95%
05:59:59 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 47,600
  • Bid/Ask: 104.0 / 104.0
  • Day's Range: 102.0 - 105.0
Type:  Equity
Market:  Japan
ISIN:  JP3548740004 
D.Western Therapeutics Institute 104.0 -1.0 -0.95%

D.Western Therapeutics Institute Inc Company Profile

 
Get an in-depth profile of D.Western Therapeutics Institute Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

20

Equity Type

ORD

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.

Contact Information

Address CK21 Hirokoujifushimi Bldg. 7th Floor
1-18-11, Nishiki Naka-ku Nagoya,460-0003
Japan
Phone 81 5 2218 8785
Fax 81 5 2202 1866

Top Executives

Name Age Since Title
Yuichi Hidaka 51 2008 President, CEO & Representative Director
Yoshiyuki Yamakawa 62 2010 Independent Outside Director
Yasumi Uchida - - Member of Scientific Advisory Board
Walter J. Chazin - - Member of Scientific Advisory Board
Masaaki Suzuki - - Member of Scientific Advisory Board
Yuta Ito 45 - Director
Sayako Matsubara - - CFO & Director
Arata Uemura - - Member of Scientific Advisory Board
Anthony R. Means - - Member of Scientific Advisory Board
Takao Aida 81 2012 Independent Outside Director
Tasuku Honjyo - - Member of Scientific Advisory Board
Yasuhiko Ito - - Member of Scientific Advisory Board
Masato Shibuya - - Member of Scientific Advisory Board
Eisaku Nakamura 63 2018 Independent Outside Director
Satoshi Aoki 68 2020 Independent Outside Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4576 Comments

Write your thoughts about D.Western Therapeutics Institute Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email